Report
Luis Arredondo
EUR 100.00 For Business Accounts Only

ROVI: 4Q’23 RESULTS, CHANGE OF RECOMMENDATION TO SELL AND T.P. UPGRADE (ANÁLISIS BANCO SABADELL)

4Q'23 vs. 4Q'22 Results
Sales: € 234.6 M (-3.1% vs. -8.4% BS(e) and -7.8% consensus);
EBITDA: € 73.3 M (-30.2% vs. -29.9% BS(e) and -37.3% consensus);
EBIT: € 66.9 M (-32.6% vs. -31.9% BS(e) and -38.9% consensus);
Net Profit: € 51.5 M (-34.1% vs. -33.3% BS(e) and -39.6% consensus);
FY2023 vs. FY2022 Results
Sales: € 829.5 M (+1.4% vs. -0.1% BS(e) and 0.0% consensus);
EBITDA: € 244.5 M (-12.3% vs. -12.2% BS(e) and -15.0% consensus);
EBIT: € 220.3 M (-13.9% vs. -13.7% BS(e) and -16.4% consensus);
Net Profit: € 170.3 M (-14.7% vs. -14.4% BS(e) and -16.9% consensus);
Underlying
Laboratorios Farmaceuticos Rovi S.A.

Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.

Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch